House Bill 2136, also known as Senate Bill 2556, mandates that by January 1, 2027, the Tennessee Department of Health must compile and submit a report detailing each medication approved by the federal Food and Drug Administration (FDA) specifically for women's health. This report will include a synopsis of each medication and is to be delivered to both the Speaker of the Senate and the Speaker of the House of Representatives.

The bill emphasizes the importance of transparency and information dissemination regarding women's health medications, ensuring that state legislative leaders are informed about the options available to women. The act will take effect immediately upon becoming law, highlighting its urgency in addressing women's health issues.